Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study | Zendy

Michihiro Hide | Zendy; Akiko Yagami | Zendy; Michinori Togawa | Zendy; Akihiro Saito | Zendy; Masutaka Furue | Zendy

Open Access

Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study

Author(s) -

Michihiro Hide,

Akiko Yagami,

Michinori Togawa,

Akihiro Saito,

Masutaka Furue

Publication year - 2016

Publication title -

allergology international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.49

H-Index - 58

eISSN - 1440-1592

pISSN - 1323-8930

DOI - 10.1016/j.alit.2016.08.004

Subject(s) - medicine , placebo , antihistamine , clinical endpoint , randomized controlled trial , dermatology life quality index , multicenter study , rash , adverse effect , anesthesia , alternative medicine , pathology , disease

Bilastine, a novel non-sedating second-generation H 1 -antihistamine, has been widely used in the treatment of allergic rhinoconjunctivitis and urticaria with a recommended dose of 20 mg once daily in most European countries since 2010. We evaluated its efficacy and safety in Japanese patients with chronic spontaneous urticaria (CSU).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research